FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016111806> ?p ?o ?g. }

• W2016111806 endingPage "221.e1" @default.
• W2016111806 startingPage "214" @default.
• W2016111806 abstract "In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF. In this post hoc analysis, we assessed the effects of ruxolitinib treatment on measures of metabolic and nutritional status.Patients were randomized to receive ruxolitinib (n = 155; 15 or 20 mg twice a day for patients with baseline platelet counts of 100-200 × 10(9)/L or > 200 × 10(9)/L, respectively) or placebo (n = 154). The primary end point was the proportion of patients with a ≥ 35% spleen volume reduction from baseline to week 24. A secondary end point was the proportion of patients with ≥ 50% improvement in Total Symptom Score (TSS) from baseline to week 24, measured using the modified Myelofibrosis Symptom Assessment Form version 2.0. Weight, cholesterol, and albumin were measured at specified time points throughout the study.Compared with placebo, ruxolitinib treatment was associated with increased weight (mean change: 3.9 kg vs. -1.9 kg), total cholesterol (mean percentage change: 26.4% vs. -3.3%), and albumin levels (mean percentage change: 5.8% vs. -1.7%) at week 24; sustained improvements were observed with longer-term ruxolitinib therapy. Relative to placebo, increases in mean weight, total cholesterol, and albumin levels were observed with ruxolitinib treatment regardless of the degree of spleen volume and TSS reductions at 24 weeks.Treatment with ruxolitinib improved measures of metabolic and nutritional status of patients with intermediate-2 or high-risk MF." @default.
• W2016111806 created "2016-06-24" @default.
• W2016111806 creator A5039057642 @default.
• W2016111806 creator A5059677466 @default.
• W2016111806 creator A5065621786 @default.
• W2016111806 creator A5067214379 @default.
• W2016111806 creator A5067595638 @default.
• W2016111806 creator A5072336042 @default.
• W2016111806 creator A5074297763 @default.
• W2016111806 creator A5083137126 @default.
• W2016111806 creator A5085521139 @default.
• W2016111806 date "2015-04-01" @default.
• W2016111806 modified "2023-10-13" @default.
• W2016111806 title "Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I" @default.
• W2016111806 cites W1545484310 @default.
• W2016111806 cites W1896432851 @default.
• W2016111806 cites W1979598229 @default.
• W2016111806 cites W1984103507 @default.
• W2016111806 cites W2018254868 @default.
• W2016111806 cites W2034127653 @default.
• W2016111806 cites W2045119449 @default.
• W2016111806 cites W2049965335 @default.
• W2016111806 cites W2068141242 @default.
• W2016111806 cites W2101250980 @default.
• W2016111806 cites W2105414227 @default.
• W2016111806 cites W2106343349 @default.
• W2016111806 cites W2111141291 @default.
• W2016111806 cites W2115351357 @default.
• W2016111806 cites W2121743767 @default.
• W2016111806 cites W2123633897 @default.
• W2016111806 cites W2127559749 @default.
• W2016111806 cites W2134540087 @default.
• W2016111806 cites W2142506642 @default.
• W2016111806 cites W2149055075 @default.
• W2016111806 cites W2151027920 @default.
• W2016111806 cites W2167088056 @default.
• W2016111806 cites W2171468656 @default.
• W2016111806 cites W2317184793 @default.
• W2016111806 cites W2326795317 @default.
• W2016111806 cites W2498175393 @default.
• W2016111806 cites W2535500964 @default.
• W2016111806 cites W2560432139 @default.
• W2016111806 cites W4241096387 @default.
• W2016111806 doi "https://doi.org/10.1016/j.clml.2014.12.008" @default.
• W2016111806 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4418454" @default.
• W2016111806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25682576" @default.
• W2016111806 hasPublicationYear "2015" @default.
• W2016111806 type Work @default.
• W2016111806 sameAs 2016111806 @default.
• W2016111806 citedByCount "57" @default.
• W2016111806 countsByYear W20161118062015 @default.
• W2016111806 countsByYear W20161118062016 @default.
• W2016111806 countsByYear W20161118062017 @default.
• W2016111806 countsByYear W20161118062018 @default.
• W2016111806 countsByYear W20161118062019 @default.
• W2016111806 countsByYear W20161118062020 @default.
• W2016111806 countsByYear W20161118062021 @default.
• W2016111806 countsByYear W20161118062022 @default.
• W2016111806 countsByYear W20161118062023 @default.
• W2016111806 crossrefType "journal-article" @default.
• W2016111806 hasAuthorship W2016111806A5039057642 @default.
• W2016111806 hasAuthorship W2016111806A5059677466 @default.
• W2016111806 hasAuthorship W2016111806A5065621786 @default.
• W2016111806 hasAuthorship W2016111806A5067214379 @default.
• W2016111806 hasAuthorship W2016111806A5067595638 @default.
• W2016111806 hasAuthorship W2016111806A5072336042 @default.
• W2016111806 hasAuthorship W2016111806A5074297763 @default.
• W2016111806 hasAuthorship W2016111806A5083137126 @default.
• W2016111806 hasAuthorship W2016111806A5085521139 @default.
• W2016111806 hasBestOaLocation W20161118061 @default.
• W2016111806 hasConcept C126322002 @default.
• W2016111806 hasConcept C141071460 @default.
• W2016111806 hasConcept C142724271 @default.
• W2016111806 hasConcept C168563851 @default.
• W2016111806 hasConcept C203092338 @default.
• W2016111806 hasConcept C204787440 @default.
• W2016111806 hasConcept C27081682 @default.
• W2016111806 hasConcept C2776112149 @default.
• W2016111806 hasConcept C2780007613 @default.
• W2016111806 hasConcept C2780076729 @default.
• W2016111806 hasConcept C67761136 @default.
• W2016111806 hasConcept C71924100 @default.
• W2016111806 hasConcept C90924648 @default.
• W2016111806 hasConceptScore W2016111806C126322002 @default.
• W2016111806 hasConceptScore W2016111806C141071460 @default.
• W2016111806 hasConceptScore W2016111806C142724271 @default.
• W2016111806 hasConceptScore W2016111806C168563851 @default.
• W2016111806 hasConceptScore W2016111806C203092338 @default.
• W2016111806 hasConceptScore W2016111806C204787440 @default.
• W2016111806 hasConceptScore W2016111806C27081682 @default.
• W2016111806 hasConceptScore W2016111806C2776112149 @default.
• W2016111806 hasConceptScore W2016111806C2780007613 @default.
• W2016111806 hasConceptScore W2016111806C2780076729 @default.
• W2016111806 hasConceptScore W2016111806C67761136 @default.
• W2016111806 hasConceptScore W2016111806C71924100 @default.
• W2016111806 hasConceptScore W2016111806C90924648 @default.
• W2016111806 hasIssue "4" @default.
• W2016111806 hasLocation W20161118061 @default.

• next